immunogenicity

Clinical Development Strategies for Antibody-Drug Conjugates (ADCs)

by
Clinical Development Strategies for Antibody-Drug Conjugates (ADCs)

Due to the differences in selecting target antigens, effective payloads, linkers, and conjugation methods for antibody-drug conjugates (ADCs), there is structural diversity and complexity. Moreover, ADCs cannot simply be equated to a combination of antibodies and effective payloads, as there are numerous challenges in clinical development, including the complexity of pharmacokinetics, insufficient tumor targeting, payload … Read more

Clinical Development Strategies for Antibody-Drug Conjugates (ADCs)

by
Clinical Development Strategies for Antibody-Drug Conjugates (ADCs)

Due to the differences in selecting target antigens, effective payloads, linkers, and conjugation methods for antibody-drug conjugates (ADCs), there is structural diversity and complexity. Moreover, ADCs cannot simply be equated to a combination of antibody drugs and effective payloads, as there are numerous challenges in clinical development, including the complexity of pharmacokinetics, insufficient tumor targeting, … Read more

The Continuous Evolution of LNPs

by
The Continuous Evolution of LNPs

Research Background Lipid nanoparticles (LNPs) are an ideal carrier for delivering various drugs with poor in vivo stability, and they are widely used in drug development strategies for proteins, nucleic acids, and more. The launch of the world’s first siRNA drug, Patisiran, marked the transition of LNPs from laboratory research to clinical application, further highlighting … Read more

From Single Target to Multidimensional Breakthrough: The New Landscape and Strategic Evolution of Next-Generation ADC Drug Bioanalysis

by
From Single Target to Multidimensional Breakthrough: The New Landscape and Strategic Evolution of Next-Generation ADC Drug Bioanalysis

With the breakthrough progress of novel structures such as bispecific ADCs and dual payload ADCs, ADC drugs have transitioned from “single-target precision strikes” to a new era of “multidimensional collaborative operations.” These innovative designs greatly expand therapeutic potential but also make their molecular structures, mechanisms of action, and in vivo fates unprecedentedly complex. In this … Read more

Opportunities for Newcomers in ADC Drugs Amid Challenges!

by
Opportunities for Newcomers in ADC Drugs Amid Challenges!

Click to follow Xiaobai Learning MedicineIntroduction: Since the approval of the first ADC drug Mylotarg® (Gemtuzumab Ozogamicin) in 2000, the number of ADC drugs has exploded, with 14 types of ADCs approved for market, and hundreds of ADC drugs undergoing clinical trials for various tumor indications. While ADCs are effective, their clinical development and application … Read more

Key Points and Challenges in PK/PD Studies of ADC Drugs

by
Key Points and Challenges in PK/PD Studies of ADC Drugs

Click the blue text above to follow us IntroductionAntibody-drug conjugates (ADC) consist of antibodies, linkers, and small molecule toxins. While they possess the advantages of high targeting ability and high cytotoxicity, their structural diversity and complexity, as well as the low levels of small molecule toxins released in the circulatory system, present numerous challenges for … Read more

Discussing Immunogenicity of ADCs

by
Discussing Immunogenicity of ADCs

â–‰ Introduction Protein drugs have the potential to induce immunogenicity, which can affect efficacy and even endanger life. New paradigms in biotherapy, such as antibody-drug conjugates (ADC), fusion proteins, and pegylation carry non-native human protein sequences and/or structural motifs, which may increase their immunogenicity risk. Therefore, comprehensive risk assessment, strategies, and analysis are needed to … Read more

Immunogenicity of ADC Drugs

by
Immunogenicity of ADC Drugs

Introduction Protein drugs have the potential to induce immunogenicity, which can affect efficacy and even jeopardize life. New models of biotherapy, such as antibody-drug conjugates (ADC), fusion proteins, and pegylation, carry non-native human protein sequences and/or structural motifs, which may increase their immunogenicity risk. Therefore, comprehensive risk assessments, strategies, and analyses are needed to monitor … Read more

From ADC to DAC: Tackling the ‘Undruggable’ Lifeline? (Data Updated to AACR 2025)

by
From ADC to DAC: Tackling the 'Undruggable' Lifeline? (Data Updated to AACR 2025)

In previous discussions about dual payloads, we mentioned that payload diversity is a crucial consideration in the future development of ADCs (ADC: Payload Evolution and Dual Payload Strategy). There are two main reasons for this: first, the existing toxin payloads have relatively singular modes of action, and treatment strategies after drug resistance need to be … Read more

Sustained Efficacy of Biologics in Psoriasis

by
Sustained Efficacy of Biologics in Psoriasis

“This article is for medical professionals only” As the application of biologics in psoriasis continues to become widespread, have you had such experiences in your clinical work? “Early patients show significant clinical efficacy when using biologics, but over time, a certain proportion of patients always exhibit a decline in efficacy?” What is behind this? Let’s … Read more